非肌层浸润性膀胱癌维持灌注治疗的患者依从性
该研究回顾2000至2013年接受膀胱内灌注治疗的非肌层浸润性尿路上皮癌患者记录,排除肿瘤复发或进展者,分析依从性。共729例患者开始861个诱导周期,63%用BCG,37%用MMC。6周诱导完成率BCG为86%、MMC为87%;BCG维持方案完成率低,SWOG方案仅10%完成全部21次,月度方案55%完成全部9次;MMC月度维持47%完成。多因素分析显示既往治疗后的复发预测依从性。结论认为临床实践中灌注治疗依从性低,尤其长疗程方案。
要点
- 6周诱导治疗完成率BCG为86%、MMC为87%。
- BCG的SWOG维持方案仅10%完成全部21次治疗。
- BCG月度方案55%完成全部9次,MMC月度维持47%完成。
核心结论
- 临床实践中膀胱内灌注治疗依从性低,尤其长疗程方案。
研究设计与样本
- 回顾性队列研究,纳入2000至2013年接受膀胱内灌注治疗的非肌层浸润性尿路上皮癌患者,排除肿瘤复发或进展者。
- 共729例患者开始861个诱导周期,63%用BCG,37%用MMC。
主要发现
- 6周诱导治疗完成率BCG为86%、MMC为87%。
- BCG队列中161例(35%)在诱导后开始SWOG维持方案,其中16例(10%)完成全部21次治疗。
- BCG月度方案87例(19%)开始,48例(55%)完成全部9次治疗。
- MMC治疗270例开始,97例(36%)开始月度维持治疗,46例(47%)完成治疗。
- 月度维持治疗(MMC或BCG)的中位灌注次数为7次,分配至3年BCG方案的中位灌注次数为9次。
临床怎么用
- 临床中应关注膀胱内灌注治疗(尤其长疗程维持方案)的依从性,识别既往治疗后复发等预测因素并加强管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess patient adherence to intravesical instillation therapy for nonmuscle invasive urothelial carcinoma outside of clinical trials. MATERIALS AND METHODS: We reviewed the records of patients from 2000 to 2013 who received intravesical therapy for nonmuscle invasive urothelial carcinoma. Patients with evidence of tumor recurrence or progression were excluded. We performed univariable and multivariable regression analyses to predict adherence to intravesical therapy. RESULTS: A total of 729 patients started 861 induction cycles, 63% with bacillus Calmette-Guèrin (BCG) and 37% with mitomycin C (MMC). The rate of completion of 6 weeks induction therapy with BCG and MMC was similar (86% and 87%, respectively). Within the BCG cohort, 161 (35%) patients commenced the Southwest Oncology Group (SWOG) maintenance protocol after induction and 16 (10%) completed all 21 treatments. A monthly protocol for BCG was started by 87 patients (19%) and 48 (55%) completed all 9 treatments. MMC therapy was started in 270 patients, 97 of whom (36%) commenced monthly maintenance treatment, and 46 (47%) completed treatments. Median number of instillations was 7 for patients undergoing monthly maintenance therapy (MMC or BCG) and 9 for patients allocated to 3 years BCG. On multivariable analysis, recurrence after prior treatment of urothelial carcinoma was predictive of patients' adherence to treatment. CONCLUSION: Compliance with intravesical therapy is low in clinical practice, notably for longer treatment schedules.
引用
- Tapiero S, Helfand A, Kedar D, et al. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer. Urology. 2018. PMID: 29792974. doi:10.1016/j.urology.2018.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。